Peer-reviewed veterinary case report
Analyzing Lymphoma Development and Progression Using HDACi in Mouse Models.
- Journal:
- Methods in molecular biology (Clifton, N.J.)
- Year:
- 2023
- Authors:
- Piskor, Eva-Maria et al.
- Affiliation:
- Institute of Biochemistry and Biophysics · Germany
Abstract
Besides the physiological role of histone deacetalylases in maintaining normal cellular integrity, the acetylation landscape is changed in cancer cells, which has been implicated as a potential target in cancer therapy. The overexpression of certain HDACs correlates with specific cancer types. Therefore, the development of specific HDAC inhibitors may extend the therapeutic strategy for cancer therapy. Here, we describe how to investigate the therapeutic potential of specific HDACi by treatment in a mouse model for B-cell lymphoma, exemplified by the HDAC6 inhibitor Marbostat-100.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/36255614/